§ Claim under review · Release
"Flow Neuroscience has launched a $2,200 prescription headset in the US, FDA-approved, designed to treat depression at home using tDCS (transcranial direct current stimulation) that sends a weak electrical current through scalp electrodes to stimulate mood-related brain areas."
Verdict
Mostly accurate
Confidence
MediumSummary
This one holds up. Flow Neuroscience really did launch its FL-100 headset in the United States, available by prescription from September 1 2026, and the FDA record confirms it received full Premarket Approval on December 8 2025. The post's use of "FDA-approved" is actually more precise than much of the press coverage, which described it as merely cleared. The device works as described, sending a weak electrical current through scalp electrodes to stimulate a mood-related brain region. Two details are missing. The $2,200 is reported as the cost of an initial 10-week treatment course, with about $325 for each additional four weeks, not a one-off purchase of a gadget. And the approved use is narrower than "depression," covering adults with moderate to severe major depression who are not considered resistant to medication, so people with long-term treatment-resistant depression may not be eligible. One further note: the post is branded as AI news, but there is no artificial intelligence in this product. It is electrical brain stimulation with a companion app.
The readings
key figures from the evidencepatient cost of initial 10-week treatment course
cost per additional four weeks of treatment
earlier projected US retail price (December 2025 guidance)
Why this verdict
Evidence
The regulatory element checks out at the strongest level available. FDA's Summary of Safety and Effectiveness Data for PMA P230024 states that CDRH issued an approval order on December 8, 2025, and describes the device trade name as Flow FL-100, a cranial electrotherapy stimulator for the treatment of depression using transcranial direct current stimulation, which delivers low-intensity direct electrical current to specific areas of the brain via electrodes placed on the scalp.
A news item in Brain Stimulation records that on Dec 8, 2025 the FDA approved the device for "moderate to severe major depressive disorder (MDD) in the current episode, either as monotherapy or as an adjunctive treatment, in patients 18 years and older who are not considered treatment refractory to medication," and notes this is the first FDA premarket approval for a home-use device of this kind.
The US launch is confirmed on the company's own channel. Flow's press release states that FL-100 is now available by prescription across the United States and that it became available from September 1, 2026, and describes the product as combining tDCS with a companion app for treatment delivery, symptom tracking and clinician monitoring.
The same release states the device is approved in the United States under FDA approval P230024 and is authorized for marketing in the UK, Europe and Australia, and that the headset is intended for moderate to severe MDD in the current episode, as monotherapy or adjunctive treatment, in patients 18 and older who are not considered treatment refractory.
On price, the strongest source is trade journalism rather than a vendor pricing page. Citeline Medtech Insight reports the device launched in the US at a patient cost of $2,200 for an initial 10-week course and $325 for every additional four weeks of treatment.
Wired's coverage is summarized as the device being FDA approved and potentially helping people get off antidepressants, "but it costs $2,200."
Notably, earlier company guidance was far lower. In December 2025 reporting, Flow expected US availability by mid-2026 at about $500 , and Psychiatric Times reported a projected US retail price of between $500 and $800 .
Findings
✓ What's accurate 6
- Flow Neuroscience has launched the device in the US, prescription-only, confirmed on the company's own channel and dated from September 1 2026.
- "FDA-approved" is the correct term here, not a loose usage. This is a full Premarket Approval, the FDA's most demanding device pathway. Several outlets that wrote "cleared" were less precise than this post.
- The mechanism description is accurate: tDCS delivering a weak direct current through scalp electrodes, targeting the left dorsolateral prefrontal cortex, an area the company describes as underactive in depression.
- At-home use during scheduled sessions, with clinician oversight, matches the approved use.
- The $2,200 figure matches both Wired and specialist trade reporting.
- The non-drug framing, usable alone or alongside antidepressants, matches the approved indication language.
≈ What's misleading 4
- **Omitted qualifier:** the post says the headset is "designed to treat depression" and that doctors can prescribe it to "eligible patients" without saying what eligible means. The approved indication is narrower: adults 18 and older, moderate to severe MDD in the current episode, and specifically not patients considered treatment refractory to medication. A reader with long-term treatment-resistant depression, the group most likely to be searching for alternatives, may be outside the indication.
- **Omitted qualifier:** the $2,200 is reported as the price of an initial 10-week treatment course with a further $325 per additional four weeks, not a one-time hardware purchase. "A $2,200 headset" reads as a device price and understates ongoing cost for anyone continuing treatment.
- **Capability extrapolation, mild:** "treat depression at home" compresses a clinician-supervised, prescription treatment program with remote symptom monitoring into a consumer-device framing. The approved product is a supervised care pathway, not a self-directed gadget.
- **Not in the canonical list, but material:** the post is branded "AI NEWS" and published by an AI newsletter account. Nothing in the FDA approval record or the company's launch release describes artificial intelligence as a component of the device or its companion app. The device is electrical neurostimulation. The AI framing is a channel-fit label, not a property of the product.
? What's uncertain 4
- The $2,200 figure and the $325 renewal cost were not confirmed against Flow's official US pricing page, which was not retrieved. Both figures rest on Wired and Citeline reporting.
- Whether $2,200 is a uniform national price or varies by telehealth pathway, insurer, or HSA/FSA treatment is unresolved. Insurance coverage was described in launch coverage as still developing.
- Efficacy figures circulating alongside the launch, such as a 57 to 58 percent remission rate at 10 weeks, trace to the company-sponsored EMPOWER trial published in Nature Medicine. That trial exists, but this investigation did not open the paper or the full FDA effectiveness section, so the sham-comparison detail is not independently characterized here. The claim under review does not make an efficacy assertion.
- I read only search-index excerpts of the 35-page FDA SSED, not the complete document.
Sources
7 of 8 linked to recordsFDA Premarket Approval database entry P230024, Flow FL-100
FDA Summary of Safety and Effectiveness Data, PMA P230024 (excerpts retrieved via search index, not the full 35-page PDF)
Flow Neuroscience launch press release, September 16 2026, via GlobeNewswire
Flow Neuroscience US site, "The first and only FDA approved at-home tDCS treatment for depression"
Citeline Medtech Insight, US launch and pricing
Wired, "A New Headset to Help With Depression Is Now Available in the US" (headline and dek retrieved via aggregators; full article not opened)
Brain Stimulation journal news item on the December 8 2025 approval
HIT Consultant, Healio, Medical Economics, MassDevice, Psychiatric Times